FREE DOWNLOAD: Lay Summary Whitepaper
This complimentary lay summary whitepaper will explain:
- the ins and outs of lay summary writing,
- the importance of starting a pilot program,
- a checklist for lay reviewers, and
- strategic advice for becoming more transparent.
Click on the image for the full whitepaper.
This whitepaper was authored by Manager of Disclosures Services Kasim McLain, Senior Transparency Lead and Medical Writer Jennifer Pilgrim, and Associate Manager of Corporate Quality Jessica Alamdari.
Suggested For You
perspectives
May 28th, 2025
A Season of Change: Why the REMS Industry Consortium Matters More Than Ever
perspectives
May 20th, 2025
Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors
perspectives
May 6th, 2025
Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn
perspectives
April 24th, 2025
How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy
perspectives
April 8th, 2025
Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements
perspectives
March 27th, 2025
Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs
perspectives
March 6th, 2025
Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products
perspectives
February 13th, 2025
Helping European Drug Development Companies Succeed in the US Market
perspectives
January 30th, 2025
Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned
perspectives
January 21st, 2025
REMS Modifications and Revisions: A Retrospective from the Past 12 Months
perspectives
January 9th, 2025
How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA
perspectives
January 2nd, 2025
Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations